Dataset from A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors

The main purpose of this study is to evaluate the safety of different doses of olaratumab and
to determine which dose should be used for future pediatric studies. The present study is
open to children with advanced cancer or cancer that has spread to another part of the body.
The study has three parts. In the first two parts, a specific dose of olaratumab will be
given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third
part, a specific dose of olaratumab will be given with one of three standard chemotherapy
regimens in 21 day cycles. Participants will only enroll in one part.